drugset / Trial / NCT04444362
Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)
Enrolling by invitation
500 enrolled
Nanjing Medical University
Shanghai East Hospital of Tongji University · collabThe First Affiliated Hospital of Guangzhou Medical University · collabWest China Hospital · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Cardiovascular diseases (CVDs) continue to be the primary cause of illness and death globally, emphasizing the pressing requirement for efficient prevention methods. Recent studies indicate that the gut microbiome plays a vital role in maintaining cardiovascular health, affecting the pathophysiological mechanisms related to CVDs. The potential therapeutic strategies for primary care practitioners included the modulation of the gut microbiome through dietary changes, prebiotics, and probiotics. The aim of this study was to investage the effect of gut microbiome modulation on clinical outcomes after cardiac surgery.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Intestinal Microbiota Transplant (IMT) Capsules | Unknown | — | — |